Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)

The PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor evolocumab reduced low-density lipoprotein cholesterol and cardiovascular events in the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). We investigated the efficacy and...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Circulation (New York, N.Y.) Jg. 137; H. 4; S. 338
Hauptverfasser:	Bonaca, Marc P, Nault, Patrice, Giugliano, Robert P, Keech, Anthony C, Pineda, Armando Lira, Kanevsky, Estella, Kuder, Julia, Murphy, Sabina A, Jukema, J Wouter, Lewis, Basil S, Tokgozoglu, Lale, Somaratne, Ransi, Sever, Peter S, Pedersen, Terje R, Sabatine, Marc S
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States 23.01.2018
Schlagworte:	Aged Amputation Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Anticholesteremic Agents - adverse effects Anticholesteremic Agents - therapeutic use Biomarkers - blood Cholesterol, LDL - blood Down-Regulation Dyslipidemias - blood Dyslipidemias - diagnosis Dyslipidemias - drug therapy Dyslipidemias - mortality Female Humans Limb Salvage Male Middle Aged Peripheral Arterial Disease - blood Peripheral Arterial Disease - diagnosis Peripheral Arterial Disease - mortality Peripheral Arterial Disease - therapy Proprotein Convertase 9 - antagonists & inhibitors Proprotein Convertase 9 - metabolism Risk Factors Serine Proteinase Inhibitors - adverse effects Serine Proteinase Inhibitors - therapeutic use Time Factors Treatment Outcome atherosclerosis amputation cholesterol, LDL evolocumab peripheral arterial disease PCSK9 protein, human intermittent claudication
ISSN:	1524-4539, 1524-4539
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!